Evidence map›Paper›PMID 40563902›Full record

ReviewBiology2025

AI-Driven Transcriptome Prediction in Human Pathology: From Molecular Insights to Clinical Applications.

Xiaoya Chen, Huinan Xu, Shengjie Yu, Wan Hu, Zhongjin Zhang, Xue Wang, Yue Yuan, Mingyue Wang, Liang Chen, Xiumei Lin and 2 more

Abstract readReview
In one paragraph

Review in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Special Issue "Bioinformatics of Gene Regulations and Structure-2025".International journal of molecular sciences · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. New Sights into Bioinformatics of Gene Regulations and Structure.International journal of molecular sciences · 2025
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaoya ChenBGI Research, Hangzhou 310030, China.
Huinan XuBGI Research, Hangzhou 310030, China.
Shengjie YuBGI Research, Hangzhou 310030, China.
Wan HuBGI Research, Hangzhou 310030, China.
Zhongjin ZhangBGI Research, Hangzhou 310030, China.
Xue WangBGI Research, Hangzhou 310030, China.
Yue YuanBGI Research, Hangzhou 310030, China.
Mingyue WangBGI Research, Hangzhou 310030, China.
Liang ChenBGI Research, Hangzhou 310030, China.
Xiumei LinBGI Research, Hangzhou 310030, China.
Yinlei HuKey Laboratory of the Ministry of Education for Mathematical Foundations and Applications of Digital Technology, University of Science and Technology of China, Hefei 230027, China.
Pengfei CaiBGI Research, Hangzhou 310030, China.

Funding

China Postdoctoral Science Foundation No.2023M732365National Natural Science Foundation of China 32400550
6 · The paper itself

Abstract

Gene expression regulation underpins cellular function and disease progression, yet its complexity and the limitations of conventional detection methods hinder clinical translation. In this review, we define "predict" as the AI-driven inference of gene expression levels and regulatory mechanisms from non-invasive multimodal data (e.g., histopathology images, genomic sequences, and electronic health records) instead of direct molecular assays. We systematically examine and analyze the current approaches for predicting gene expression and diagnosing diseases, highlighting their respective advantages and limitations. Machine learning algorithms and deep learning models excel in extracting meaningful features from diverse biomedical modalities, enabling tools like PathChat and Prov-GigaPath to improve cancer subtyping, therapy response prediction, and biomarker discovery. Despite significant progress, persistent challenges-such as data heterogeneity, noise, and ethical issues including privacy and algorithmic bias-still limit broad clinical adoption. Emerging solutions like cross-modal pretraining frameworks, federated learning, and fairness-aware model design aim to overcome these barriers. Case studies in precision oncology illustrate AI's ability to decode tumor ecosystems and predict treatment outcomes. By harmonizing multimodal data and advancing ethical AI practices, this field holds immense potential to propel personalized medicine forward, although further innovation is needed to address the issues of scalability, interpretability, and equitable deployment.

Indexed as

artificial intelligencedeep learningmultimodal data fusionprecision medicinetranscriptome prediction

Identifiers

PMID40563902
PMCPMC12189417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.